Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7966 to 7980 of 8904 results

  1. Baloxavir marboxil for treating influenza in babies under 1 year [ID6555]

    Discontinued Reference number: GID-TA11712

    Technology appraisal guidance
    Discontinued

  2. Baloxavir marboxil for treating and preventing influenza in people 3 weeks to 11 years [ID6554]

    In development Reference number: GID-TA11732 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Antimicrobial prescribing: cefiderocol (ES31)

    This evidence summary has been updated and replaced by NICE antimicrobial health technology evaluation guidance on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.

    Withdrawn advice

  4. Parkinson's disease with motor fluctuations: safinamide (ES6)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Withdrawn advice

  5. Parkinson's disease with end-of-dose motor fluctuations: opicapone (ES9)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Withdrawn advice

  6. Clostridium difficile infection: fidaxomicin (ESNM1)

    This advice has been updated and replaced by NICE guideline NG199.

    Withdrawn advice

  7. Type 2 diabetes: lixisenatide (ESNM10)

    This evidence summary has been updated and replaced by NICE advice ESNM26.

    Withdrawn advice

  8. Acute diarrhoea in adults: racecadotril (ESNM11)

    This evidence summary has been withdrawn because the product is no longer available in the UK.

    Withdrawn advice

  9. Acute diarrhoea in children: racecadotril as an adjunct to oral rehydration (ESNM12)

    This evidence summary has been withdrawn because the product is no longer available in the UK.

    Withdrawn advice

  10. Actinic keratosis: ingenol mebutate gel (ESNM14)

    This evidence summary has been withdrawn as the licence of ingenol mebutate gel has been suspended.

    Withdrawn advice

  11. Schizophrenia: lurasidone (ESNM15)

    This evidence summary has been replaced by ESNM48

    Withdrawn advice

  12. Irritable bowel syndrome with constipation in adults: linaclotide (ESNM16)

    This evidence summary has been updated and replaced by NICE guideline CG61.

    Withdrawn advice

  13. Partial-onset seizures in epilepsy: zonisamide as monotherapy (ESNM17)

    This evidence summary has been updated and replaced by NICE guideline NG217.

    Withdrawn advice

  14. Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil (ESNM18)

    This evidence summary has been updated and replaced by NICE guideline CG97.

    Withdrawn advice

  15. Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate (ESNM19)

    This evidence summary has been updated and replaced by NICE guideline NG87.

    Withdrawn advice